乳腺癌与卵巢癌预防性降低风险手术后的生活质量:系统综述与Meta分析
本系统综述与Meta分析纳入34项研究,评估降低风险乳房切除术、降低风险输卵管卵巢切除术及降低风险早期输卵管切除+延迟卵巢切除术对生活质量的影响。降低风险乳房切除术和输卵管卵巢切除术不改变或改善健康相关生活质量并减少癌症相关困扰,但分别与体象问题和性功能障碍、更年期症状相关。
要点
- 降低风险乳房切除术后健康相关生活质量不变或改善,但部分研究报告体象恶化。
- 降低风险输卵管卵巢切除术后性快感降低、性不适增加,更年期症状加重。
- 降低风险早期输卵管切除+延迟卵巢切除术可能改善性功能与更年期特异性生活质量。
核心结论
- 降低风险手术可能与生活质量结局相关。
- 降低风险乳房切除术和降低风险输卵管卵巢切除术减少癌症相关困扰,且不影响健康相关生活质量。
- 女性和临床医生应知晓降低风险乳房切除术后体象问题,以及降低风险输卵管卵巢切除术后性功能障碍和更年期症状。
- 降低风险早期输卵管切除+延迟卵巢切除术可能是减轻降低风险输卵管卵巢切除术生活质量相关风险的有前景的替代方案。
研究设计与样本
- 系统综述与Meta分析,遵循前瞻性方案(International Prospective Register of Systematic Reviews: CRD42022319782),检索MEDLINE、Embase、PubMed和Cochrane Library自建库至2023年2月。
- 采用PICOS框架,人群为乳腺癌或卵巢癌风险增高的女性,纳入报告降低风险手术后生活质量结局的研究。
- 共纳入34项研究:降低风险乳房切除术16项,降低风险输卵管卵巢切除术19项,降低风险早期输卵管切除+延迟卵巢切除术2项。
- 使用非随机研究方法学指数(MINORS)进行文献质量评价,进行定性合成和固定效应Meta分析。
主要发现
- 降低风险乳房切除术后健康相关生活质量在15项研究中的13项(N=986)不变或改善,尽管存在短期下降(N=96)。
- 降低风险输卵管卵巢切除术后健康相关生活质量在16项研究中的10项(N=1617)不变或改善,尽管存在短期下降(N=459)。
- 降低风险输卵管卵巢切除术后性功能(采用性活动问卷)在16项研究中的13项(N=1400)受影响,表现为性快感降低(-1.21 [-1.53至-0.89];N=3070)和性不适增加(1.12 [0.93-1.31];N=1400)。
- 绝经前降低风险输卵管卵巢切除术后激素替代治疗与性快感增加(1.16 [0.17-2.15];N=291)和性不适降低(-1.20 [-1.75至-0.65];N=157)相关。
- 降低风险乳房切除术后性功能在13项研究中的4项(N=147)受影响,但在9项研究(N=799)中稳定;体象在13项研究中的7项(N=605)未受影响,6项(N=391)报告恶化。
关键数值与推荐
- 降低风险乳房切除术后性快感降低(-1.21 [-1.53至-0.89];N=3070)和性不适增加(1.12 [0.93-1.31];N=1400)见于降低风险输卵管卵巢切除术后的性功能分析。
- 绝经前降低风险输卵管卵巢切除术后激素替代治疗与性快感增加(1.16 [0.17-2.15];N=291)和性不适降低(-1.20 [-1.75至-0.65];N=157)相关。
- 降低风险输卵管卵巢切除术后癌症治疗功能评估-内分泌症状评分降低(-1.96 [-2.81至-1.10];N=1745)。
临床怎么用
- 女性和临床医生应知晓降低风险乳房切除术后体象问题,以及降低风险输卵管卵巢切除术后性功能障碍和更年期症状。
- 降低风险早期输卵管切除+延迟卵巢切除术可能是减轻降低风险输卵管卵巢切除术生活质量相关风险的有前景的替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to assess the impact of risk-reducing surgery for breast cancer and ovarian cancer prevention on quality of life. We considered risk-reducing mastectomy, risk-reducing salpingo-oophorectomy, and risk-reducing early salpingectomy and delayed oophorectomy. DATA SOURCES: We followed a prospective protocol (International Prospective Register of Systematic Reviews: CRD42022319782) and searched MEDLINE, Embase, PubMed, and Cochrane Library from inception to February 2023. STUDY ELIGIBILITY CRITERIA: We followed a PICOS (population, intervention, comparison, outcome, and study design) framework. The population included women at increased risk of breast cancer or ovarian cancer. We focused on studies reporting quality of life outcomes (health-related quality of life, sexual function, menopause symptoms, body image, cancer-related distress or worry, anxiety, or depression) after risk-reducing surgery, including risk-reducing mastectomy for breast cancer and risk-reducing salpingo-oophorectomy or risk-reducing early salpingectomy and delayed oophorectomy for ovarian cancer. METHODS: We used the Methodological Index for Non-Randomized Studies (MINORS) for study appraisal. Qualitative synthesis and fixed-effects meta-analysis were performed. RESULTS: A total of 34 studies were included (risk-reducing mastectomy: 16 studies; risk-reducing salpingo-oophorectomy: 19 studies; risk-reducing early salpingectomy and delayed oophorectomy: 2 studies). Health-related quality of life was unchanged or improved in 13 of 15 studies after risk-reducing mastectomy (N=986) and 10 of 16 studies after risk-reducing salpingo-oophorectomy (N=1617), despite short-term deficits (N=96 after risk-reducing mastectomy and N=459 after risk-reducing salpingo-oophorectomy). Sexual function (using the Sexual Activity Questionnaire) was affected in 13 of 16 studies (N=1400) after risk-reducing salpingo-oophorectomy in terms of decreased sexual pleasure (-1.21 [-1.53 to -0.89]; N=3070) and increased sexual discomfort (1.12 [0.93-1.31]; N=1400). Hormone replacement therapy after premenopausal risk-reducing salpingo-oophorectomy was associated with an increase (1.16 [0.17-2.15]; N=291) in sexual pleasure and a decrease (-1.20 [-1.75 to -0.65]; N=157) in sexual discomfort. Sexual function was affected in 4 of 13 studies (N=147) after risk-reducing mastectomy, but stable in 9 of 13 studies (N=799). Body image was unaffected in 7 of 13 studies (N=605) after risk-reducing mastectomy, whereas 6 of 13 studies (N=391) reported worsening. Increased menopause symptoms were reported in 12 of 13 studies (N=1759) after risk-reducing salpingo-oophorectomy with a reduction (-1.96 [-2.81 to -1.10]; N=1745) in the Functional Assessment of Cancer Therapy - Endocrine Symptoms. Cancer-related distress was unchanged or decreased in 5 of 5 studies after risk-reducing mastectomy (N=365) and 8 of 10 studies after risk-reducing salpingo-oophorectomy (N=1223). Risk-reducing early salpingectomy and delayed oophorectomy (2 studies, N=413) led to better sexual function and menopause-specific quality of life. CONCLUSION: Risk-reducing surgery may be associated with quality of life outcomes. Risk-reducing mastectomy and risk-reducing salpingo-oophorectomy reduce cancer-related distress, and do not affect health-related quality of life. Women and clinicians should be aware of body image problems after risk-reducing mastectomy, and of sexual dysfunction and menopause symptoms after risk-reducing salpingo-oophorectomy. Risk-reducing early salpingectomy and delayed oophorectomy may be a promising alternative to mitigate quality of life-related risks of risk-reducing salpingo-oophorectomy.
引用
- Wei X, Oxley S, Sideris M, et al. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023. PMID: 37059410. doi:10.1016/j.ajog.2023.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。